Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

IMWG /ECOG Frailty Score Was a Good Indicator for ASCT Candidate Selection for NDMM in China from a Hcmmd Retrospective Study

Xingyue Wu, Chengcheng Fu, Hongmiao Shen, Hongying You, Yingying Zhai, Jing Wang, Zhi Yan, Shuang Yan, Weiqin Yao, Jiao Lu, Jingjing Shang, Song Jin, Xiaolan Shi, Lingzhi Yan, De-Pei Wu

Blood (2023) 142 (Supplement 1): 7061.

https://doi.org/10.1182/blood-2023-185763

Published: 2023

Journal Articles

Three-Year Follow-up on Efficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma

Chengcheng Fu, Wenming Chen, Zhen Cai, Lingzhi Yan, Huijuan Wang, Jingjing Shang, Yin Wu, Shuang Yan, Wen Gao, Xiaolan Shi, Xiaoyan Han, Fang Tang, Gaofeng Zheng, Yanling Wen, Xingxing Meng, Wei Zheng, Huamao Wang, Zonghai Li

Blood (2023) 142 (Supplement 1): 4845.

https://doi.org/10.1182/blood-2023-184373

Published: 2023

Journal Articles

11q Gain with t(11;14) or Alone Were Associated with Poor Prognosis in Newly-Diagnosed Multiple Myeloma Patients By SNP-Array Analysis and FISH

Blood (2023) 142 (Supplement 1): 1968.

https://doi.org/10.1182/blood-2023-184870

Published: 2023

Journal Articles

Efficacy and Safety of Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma with Renal Insufficiency in Real-World: A Non-Interventional Prospective Multicenter Observational Study

Chengcheng Fu, Jing Wang, Lingzhi Yan, Song Jin, Jingjing Shang, Xiaolan Shi, Weiqin Yao, Zhi Yan, Mingqing Zhu, De-Pei Wu

Blood (2023) 142 (Supplement 1): 6691.

https://doi.org/10.1182/blood-2023-185362

Published: 2023

Journal Articles

Speckle Tracking Echocardiography for the Diagnosis and Prognosis of Light Chain Cardiac Amyloidosis

Hongmiao Shen, Chengcheng Fu, Xingyue Wu, Hongying You, Zhi Yan, Weiqin Yao, Jiao Lu, Yingying Zhai, Jing Wang, Xiaolan Shi, Shuang Yan, Jingjing Shang, Song Jin, Lingzhi Yan, De-Pei Wu

Blood (2023) 142 (Supplement 1): 6743.

https://doi.org/10.1182/blood-2023-185767

Published: 2023

Journal Articles

CNVs Numbers Scoring System Was a Good Prognostic Risk Stratification for NDMM with Whole Genomic Mapping Array

Zhao Zeng, Chengcheng Fu, Jinlan Pan, Jiao Lu, Jingjing Shang, Zhiyu Zhang, Hongying You, Wanhui Yan, Chunxiao Wu, Qinrong Wang, Qian Wang, Lijun Wen, Song Jin, Lingzhi Yan, Suning Chen, De-pei Wu

Blood (2023) 142 (Supplement 1): 4725.

https://doi.org/10.1182/blood-2023-184504

Published: 2023

Journal Articles

Selinexor, Daratumumab and Dexamethasone for Patients with Multiple Myeloma Previously Treated with Lenalidomide at First Relapse: A Real-World Study

Yingying Zhai, Lingzhi Yan, Song Jin, Jingjing Shang, Xiaolan Shi, Weiqin Yao, Zhi Yan, Shuang Yan, De-pei Wu, Chengcheng Fu

Blood (2023) 142 (Supplement 1): 6739.

https://doi.org/10.1182/blood-2023-185540

Published: 2023

Journal Articles

Initial Safety and Efficacy of Daratumumab (DARA) in Combination with Bortezomib, Lenalidomide, and Dexamethasone in the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM) Patients with Standard Risk Who Refused to Accept ASCT As First Line in China

Chengcheng Fu, Jing Wang, Lingzhi Yan, Song Jin, Jingjing Shang, Xiaolan Shi, Weiqin Yao, Zhi Yan, De-Pei Wu

Blood (2023) 142 (Supplement 1): 6736.

https://doi.org/10.1182/blood-2023-185263

Published: 2023

Journal Articles

TP53 Gene Deletion or Mutation in Newly Diagnosed Multiple Myeloma Patients By FISH with Cytoscan Arrays and Targeted Panel Sequencing

Hongying You, Hongjie Shen, Song Jin, Qingqing Wang, Shuang Yan, Yingying Zhai, Weiqin Yao, Xiaolan Shi, Jingjing Shang, Lingzhi Yan, Ying Yao, Jing Wang, Panfeng Wang, Jinlan Pan, Depei Wu, Chengcheng Fu

Blood (2022) 140 (Supplement 1): 4325–4327.

https://doi.org/10.1182/blood-2022-159272

Published: 2022

Journal Articles

The Independent Adverse Prognostic Significance of 1q21 Gain/Amplification in Newly Diagnosed Multiple Myeloma Patients

Hongying You, Song Jin, Chunxiao Wu, Qingqing Wang, Shuang Yan, Yingying Zhai, Weiqin Yao, Xiaolan Shi, Jingjing Shang, Lingzhi Yan, Ying Yao, Jing Wang, Panfeng Wang, Jinlan Pan, Depei Wu, Chengcheng Fu

Blood (2022) 140 (Supplement 1): 10056–10057.

https://doi.org/10.1182/blood-2022-159067

Published: 2022

Journal Articles

Comparison of Next-Generation Flow Cytometry (NGF) and Next-Generation Sequencing (NGS) in the Assessment of Minimal Residual Disease in Multiple Myeloma

Qingqing Wang, Li Yao, Mingqing Zhu, Lingzhi Yan, Song Jin, Jingjing Shang, Xiaolan Shi, Yingying Zhai, Shuang Yan, Weiqin Yao, You Hongying, Depei Wu, Chengcheng Fu

Blood (2022) 140 (Supplement 1): 7249–7250.

https://doi.org/10.1182/blood-2022-157270

Published: 2022

Journal Articles

Phase 2 Suzhou MM02 Study: Chidamide with VRD Versus VRD in Newly Diagnosed High Risk Transplant Eligible Multiple Myeloma Patients

Weiqin Yao, Lingzhi Yan, Jingjing Shang, Song Jin, Xiaolan Shi, Shuang Yan, Depei Wu, Chengcheng Fu

Blood (2021) 138 (Supplement 1): 4765.

https://doi.org/10.1182/blood-2021-152390

Published: 2021

Journal Articles

Targeting 1q21 Amplification with APG2575 and Lenalidomide to Sensitize BCL-2 Inhibition with the Decrease of MCL-1 Protein in High Risk MM Models

Yan Xie, MD, Chengcheng FU, MD PhD, Lingzhi Yan, MD PhD, Song Jin, MD, Jingjing Shang, MD, Xiaolan Shi, MD PhD, Jinlan Pan, MD, Yan Yin, MS, Tingting Mao, MS, Jing Deng, PhD, Douglas D. Fang, MD PhD, Dajun Yang, MD PhD, Yifan Zhai, MD PhD, Shuang Yan, MD, Yingying Zhai, MD, Ying Yao, MD, Panfeng Wang, MD, Jing Wang, MD, Depei Wu, MDPhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-139195

Published: 2020

Journal Articles

Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study

Lingzhi Yan, Zhi Yan, Jingjing Shang, Xiaolan Shi, Song Jin, Liqing Kang, Su Qu, Jin Zhou, Huizhu Kang, Ruju Wang, Ying Yao, Jing Wang, Weiqin Yao, Guanghua Chen, Lei Yu, Depei Wu, MD PhD, Fu Cheng Cheng, MD PhD

Blood (2019) 134 (Supplement_1): 578.

https://doi.org/10.1182/blood-2019-129740

Published: 2019

Journal Articles

Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM

Blood (2019) 134 (Supplement_1): 1949.

https://doi.org/10.1182/blood-2019-131546

Published: 2019

Journal Articles

Initial Safety and Efficacy of Dose-Escalating HDACs Inhibitor Chidamide with VRD (Chi-VRD) Treatment for Newly-Diagnosed High-Risk Transplant Eligible Multiple Myeloma Patients

Jingjing Shang, Weiqin Yao, Lingzhi Yan, Xiaolan Shi, Ruju Wang, Shuang Yan, Yong Liu, Depei Wu, MD PhD, Fu Cheng Cheng, MD PhD

Blood (2019) 134 (Supplement_1): 1855.

https://doi.org/10.1182/blood-2019-129434

Published: 2019

Journal Articles

Tandom Autologous Transplantation and Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for High Risk MM: Initial Safety and Efficacy Report from a Clinical Pilot Study

Xiaolan Shi, Lingzhi Yan, Jingjing Shang, Su Qu, Liqing Kang, Jin Zhou, Song Jin, Weiqin Yao, Ying Yao, Shuang Yan, Yong Liu, Guanghua Chen, Ziling Zhu, Huirong Chang, Depei Wu, MDPhD, Lei Yu, ChengCheng Fu

Blood (2018) 132 (Supplement 1): 1009.

https://doi.org/10.1182/blood-2018-99-117964

Published: 2018

Journal Articles

The Prognostic Significance of Minimal Residual Disease Detection after Induction and ASCT to the Patients with Multiple Myeloma

Weiqin Yao, Zhu Mingqing, Yao Feirong, Lingzhi Yan, Song Jin, Jingjing Shang, Ying Yao, Shuang Yan, Depei Wu, MD PhD, ChengCheng Fu

Blood (2018) 132 (Supplement 1): 4956.

https://doi.org/10.1182/blood-2018-99-118257

Published: 2018

Journal Articles

Bortezomib, Liposome Doxorubicin and Dexamethasone (PDd) Is Superior in Safety and Not Inferior in Efficiency to Bortezomib, Doxorubicin and Dexamethasone (PAd) As Induction Therapy in New-Diagnosed Multiple Myeloma Patients: An Interim Report from China's Multicenter Study

Song Jin, Yun Xu, Jin Zhou, Jingjing Shang, Lingzhi Yan, Chengcheng Fu, Depei Wu, MD

Blood (2017) 130 (Supplement 1): 5433.

https://doi.org/10.1182/blood.V130.Suppl_1.5433.5433

Published: 2017

Journal Articles

Application of the Conditioning Regimen with Busulfan and Cyclophosphamide in Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

Yun Xu, Ying Yao, Weiqin Yao, Song Jin, Lingzhi Yan, Jingjing Shang, Chengcheng Fu, Depei Wu, MD

Blood (2017) 130 (Supplement 1): 5517.

https://doi.org/10.1182/blood.V130.Suppl_1.5517.5517

Published: 2017

NARROW

IMWG /ECOG Frailty Score Was a Good Indicator for ASCT Candidate Selection for NDMM in China from a Hcmmd Retrospective Study

Three-Year Follow-up on Efficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma

11q Gain with t(11;14) or Alone Were Associated with Poor Prognosis in Newly-Diagnosed Multiple Myeloma Patients By SNP-Array Analysis and FISH

Efficacy and Safety of Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma with Renal Insufficiency in Real-World: A Non-Interventional Prospective Multicenter Observational Study

Speckle Tracking Echocardiography for the Diagnosis and Prognosis of Light Chain Cardiac Amyloidosis

CNVs Numbers Scoring System Was a Good Prognostic Risk Stratification for NDMM with Whole Genomic Mapping Array

Selinexor, Daratumumab and Dexamethasone for Patients with Multiple Myeloma Previously Treated with Lenalidomide at First Relapse: A Real-World Study

Initial Safety and Efficacy of Daratumumab (DARA) in Combination with Bortezomib, Lenalidomide, and Dexamethasone in the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM) Patients with Standard Risk Who Refused to Accept ASCT As First Line in China

TP53 Gene Deletion or Mutation in Newly Diagnosed Multiple Myeloma Patients By FISH with Cytoscan Arrays and Targeted Panel Sequencing

The Independent Adverse Prognostic Significance of 1q21 Gain/Amplification in Newly Diagnosed Multiple Myeloma Patients

Comparison of Next-Generation Flow Cytometry (NGF) and Next-Generation Sequencing (NGS) in the Assessment of Minimal Residual Disease in Multiple Myeloma

Phase 2 Suzhou MM02 Study: Chidamide with VRD Versus VRD in Newly Diagnosed High Risk Transplant Eligible Multiple Myeloma Patients

Targeting 1q21 Amplification with APG2575 and Lenalidomide to Sensitize BCL-2 Inhibition with the Decrease of MCL-1 Protein in High Risk MM Models

Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study

Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM

Initial Safety and Efficacy of Dose-Escalating HDACs Inhibitor Chidamide with VRD (Chi-VRD) Treatment for Newly-Diagnosed High-Risk Transplant Eligible Multiple Myeloma Patients

Tandom Autologous Transplantation and Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for High Risk MM: Initial Safety and Efficacy Report from a Clinical Pilot Study

The Prognostic Significance of Minimal Residual Disease Detection after Induction and ASCT to the Patients with Multiple Myeloma

Bortezomib, Liposome Doxorubicin and Dexamethasone (PDd) Is Superior in Safety and Not Inferior in Efficiency to Bortezomib, Doxorubicin and Dexamethasone (PAd) As Induction Therapy in New-Diagnosed Multiple Myeloma Patients: An Interim Report from China's Multicenter Study

Application of the Conditioning Regimen with Busulfan and Cyclophosphamide in Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only